Veradermics, Inc
MANE · Pharmaceutical Preparations · 41.8M shares · EDGAR filings ↗
Reference price $35.97 · est. market cap ~$1.5B — last insider purchase, 2026-02-06 (estimated from the dated SEC Form 4 price × shares outstanding — not a live quote)
Grade
D44Clinical/early-stage biotech — dermatology clinical, very cash-rich.
Strengths
- Liquidity — current ratio 16.7 (93rd)
Risks
- Pre-revenue, deep losses — per metrics
- Pre-revenue/clinical-stage — history of losses & need for capital per risk factors
- Binary clinical & funding risk — per 10-K
Notable findings
- Cash burnNegative free cash flow (-71.6M)
- Insider buyingInsider buying — 27 open-market buy(s) by 5 insider(s) (cluster of 5 insiders, ~$59M, last 6mo) Form 4 ↗
- Trial resultPositive trial readout — primary endpoint met (8-K) 8-K ↗
- Notable holderHeld by 4 notable fund(s): CITADEL ADVISORS LLC, FMR LLC, GOLDMAN SACHS GROUP INC +1 more (as of 2026-03-31)
- Trial readout soonUpcoming trial readout ~2026-08 — PHASE2 · Androgenetic Alopecia
Key metrics
Return on equity
57.8%
Return on assets
-45.9%
Current ratio
16.7×
Free cash flow
-$72M
Tangible book value
-$121M
Cash & investments
$142M
Cash runway
8q
Insider transactions · last 18 months
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-02-06 | SUVRETTA CAPITAL MANAGEMENT, LLC | Buy | 11K | $35.97 |
| 2026-02-06 | SUVRETTA CAPITAL MANAGEMENT, LLC | Buy | 19K | $36.55 |
| 2026-02-05 | Waldman Reid Alexander | Conversion | 1.4K | — |
| 2026-02-05 | Longitude Capital Partners V, LLC | Conversion | 1.2M | — |
| 2026-02-05 | Longitude Capital Partners V, LLC | Conversion | 1.2M | — |
| 2026-02-05 | Longitude Capital Partners V, LLC | Conversion | 1.2M | — |
| 2026-02-05 | Longitude Capital Partners V, LLC | Buy | 193K | $17.00 |
| 2026-02-05 | Longitude Capital Partners V, LLC | Buy | 882K | $17.00 |
| 2026-02-05 | ENRIGHT PATRICK G | Conversion | 1.2M | — |
| 2026-02-05 | ENRIGHT PATRICK G | Conversion | 1.2M | — |
| 2026-02-05 | ENRIGHT PATRICK G | Conversion | 1.2M | — |
| 2026-02-05 | ENRIGHT PATRICK G | Buy | 193K | $17.00 |
| 2026-02-05 | ENRIGHT PATRICK G | Buy | 882K | $17.00 |
| 2026-02-05 | Durso Timothy August | Conversion | 1.5K | — |
| 2026-02-05 | CHILDS JOHN W | Buy | 294K | $17.00 |
| 2026-02-05 | SUVRETTA CAPITAL MANAGEMENT, LLC | Buy | 3.8K | $36.07 |
| 2026-02-05 | SUVRETTA CAPITAL MANAGEMENT, LLC | Buy | 19K | $36.93 |
| 2026-02-05 | SUVRETTA CAPITAL MANAGEMENT, LLC | Buy | 39K | $37.63 |
| 2026-02-05 | SUVRETTA CAPITAL MANAGEMENT, LLC | Buy | 18K | $38.67 |
| 2026-02-05 | SUVRETTA CAPITAL MANAGEMENT, LLC | Buy | 17K | $39.80 |
| 2026-02-05 | Grant-Kels Jane M. | Conversion | 2.5K | — |
| 2026-02-05 | Coric Vlad | Conversion | 34K | — |
| 2026-02-05 | Coric Vlad | Conversion | 34K | — |
| 2026-02-05 | Coric Vlad | Conversion | 149K | — |
| 2026-02-05 | Coric Vlad | Conversion | 149K | — |
| 2026-02-05 | Coric Vlad | Conversion | 78K | — |
| 2026-02-05 | Coric Vlad | Conversion | 78K | — |
| 2026-02-05 | Coric Vlad | Conversion | 117K | — |
| 2026-02-05 | Coric Vlad | Buy | 59K | $17.00 |
| 2026-02-05 | Coric Vlad | Buy | 59K | $17.00 |
| 2026-02-05 | CHILDS JOHN W | Conversion | 480K | — |
| 2026-02-05 | CHILDS JOHN W | Conversion | 907K | — |
| 2026-02-05 | CHILDS JOHN W | Conversion | 521K | — |
| 2026-02-05 | CHILDS JOHN W | Buy | 294K | $17.00 |
| 2026-02-04 | SUVRETTA CAPITAL MANAGEMENT, LLC | Buy | 15K | $36.27 |
| 2026-02-04 | SUVRETTA CAPITAL MANAGEMENT, LLC | Buy | 53K | $37.11 |
| 2026-02-04 | SUVRETTA CAPITAL MANAGEMENT, LLC | Buy | 26K | $38.09 |
| 2026-02-04 | SUVRETTA CAPITAL MANAGEMENT, LLC | Buy | 18K | $38.90 |
| 2026-02-04 | SUVRETTA CAPITAL MANAGEMENT, LLC | Buy | 1.7K | $34.25 |
| 2026-02-04 | SUVRETTA CAPITAL MANAGEMENT, LLC | Buy | 1.8K | $34.74 |
| 2026-02-04 | SUVRETTA CAPITAL MANAGEMENT, LLC | Buy | 2.5K | $36.27 |
| 2026-02-04 | SUVRETTA CAPITAL MANAGEMENT, LLC | Buy | 9.2K | $37.11 |
| 2026-02-04 | SUVRETTA CAPITAL MANAGEMENT, LLC | Buy | 4.5K | $38.09 |
| 2026-02-04 | SUVRETTA CAPITAL MANAGEMENT, LLC | Buy | 3.2K | $38.90 |
| 2026-02-04 | SUVRETTA CAPITAL MANAGEMENT, LLC | Buy | 10K | $34.25 |
| 2026-02-04 | SUVRETTA CAPITAL MANAGEMENT, LLC | Buy | 11K | $34.74 |
All non-derivative Form 4 activity (SEC), newest first.
Clinical trials
| Trial | Title | Phase | Status | Primary completion |
|---|---|---|---|---|
| NCT07146022 ↗ | Safety and Efficacy of VDPHL01 in Females With Androgenetic Alopecia (AGA) Androgenetic Alopecia (AGA), Androgenetic Alopecia | PHASE3 | Recruiting | 2027-06-01 |
| NCT06972264 ↗ | Safety and Efficacy of VDPHL01 in Males With AGA Androgenetic Alopecia, AGA | PHASE3 | Active Not Recruiting | 2026-12-01 |
| NCT06527365 ↗ | Safety and Efficacy of VDPHL01 in Males and Females With AGA Androgenetic Alopecia, AGA | PHASE2 | Active Not Recruiting | 2026-08-01 |
| NCT06724614 ↗ | Efficacy and Safety of VDPHL01 in Males With AGA Androgenetic Alopecia, AGA | PHASE2/PHASE3 | Active Not Recruiting | 2026-02-01 |
| NCT05799157 ↗ | Safety and Efficacy of VDMN-21 Patch in Subjects With Common Warts Verruca Vulgaris, Warts | PHASE2 | Completed | 2025-02-25 |
Source: ClinicalTrials.gov (U.S. NIH) · active studies first.
Notable events (8-K)
Recent filings
| Form | Filed | Period | Accession |
|---|---|---|---|
| 10-Q | 2026-05-12 | 2026-03-31 | 0001827635-26-000019 ↗ |
| 8-K | 2026-05-12 | 2026-05-12 | 0001827635-26-000016 ↗ |
| 8-K | 2026-05-01 | 2026-05-01 | 0001628280-26-029376 ↗ |
| 8-K | 2026-04-27 | 2026-04-27 | 0001628280-26-027629 ↗ |
| 8-K | 2026-04-27 | 2026-04-27 | 0001628280-26-027354 ↗ |
| 10-K | 2026-03-30 | 2025-12-31 | 0001827635-26-000013 ↗ |
| 8-K | 2026-03-30 | 2026-03-30 | 0001827635-26-000010 ↗ |
| 8-K | 2026-02-05 | 2026-02-05 | 0001628280-26-005800 ↗ |